ESMO World Congress on Gastrointestinal Cancer 2021 (ESMO GI 2021)

Reduced-dose S1 + oxaliplatin combo therapy preserves QoL in older patients with mCRC

Elaine Soliven, 20210910000000

The combination of reduced-dose S1 and oxaliplatin (SOx) chemotherapy preserves quality of life (QoL) and physical function in vulnerable older patients with metastatic colorectal cancer (mCRC), according to a subgroup analysis of the NORDIC9* study presented at ESMO GI 2021.

Antibiotic exposure tied to increased early-onset CRC risk

Roshini Claire Anthony, 20210909180001

Antibiotic exposure may be associated with an increased risk of early-onset colorectal cancer (CRC), according to a study from Scotland presented at ESMO GI 2021.

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

Elaine Soliven, 20210908000000

Second-line treatment with tislelizumab improves overall survival (OS) in patients from Europe/North America (EU/NA) with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy, according to subgroup analysis of the RATIONALE 302* study presented at ESMO GI 2021.

Lenvatinib benefit extends to Child-Pugh B HCC patients

Pearl Toh, 20210904150000

Lenvatinib confers better clinical outcomes than sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) even when their liver function deteriorates to Child-Pugh B after initiation of treatment, according to a post hoc analysis of the REFLECT study.

PRECONNECT final analysis underline potential of trifluridine/tipiracil for metastatic CRC

Audrey Abella, 20210903100000

In the final analysis of the phase IIIb PRECONNECT study presented at ESMO GI 2021, a chemotherapeutic regimen comprising trifluridine/tipiracil (FTD/TPI) continued to show favourable efficacy and safety for individuals with previously treated metastatic colorectal cancer (mCRC), with no new safety concerns.

Ramucirumab + paclitaxel extends survival in gastric cancer, regardless of liver metastasis

Pearl Toh, 20210902150000

Adding the VEGFR*-2 antagonist ramucirumab to paclitaxel extends survival of patients with advanced gastric/GEJ** adenocarcinoma compared with paclitaxel alone, regardless of liver metastasis status, according to a post hoc analysis of the RAINBOW*** trial presented at the ESMO GI 2021 Congress.

Nab-paclitaxel/gemcitabine combo boosts OS in resected pancreatic cancer

Elvira Manzano, 20210902000000

Adjuvant treatment with nab-paclitaxel and gemcitabine improved 5-year overall survival (OS) by over 4 months vs gemcitabine alone in patients with resected pancreatic cancer, an updated analysis of the phase III APACT* trial has shown.

Chemo dose may affect survival in obese CRC patients

Roshini Claire Anthony, 20210901180001

Obese patients with colorectal cancer (CRC) may be receiving lower cumulative doses of chemotherapy than non-obese patients which may impact their survival outcomes, according to results of a study from the OCTOPUS consortium.

Pembrolizumab-trastuzumab-chemo a new treatment alternative for gastric cancer?

Audrey Abella, 20210901050441

In a prespecified interim analysis of the phase III KEYNOTE-811 study presented at ESMO GI 2021, the addition of pembrolizumab to standard of care (SoC) first-line therapy comprising trastuzumab and chemotherapy led to a significant improvement in overall response rate (ORR) in previously untreated individuals with HER2-positive, metastatic gastric or gastroesophageal junction (G/GEJ) cancer.